ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer
Sweeney, C.J.
Clinical Advances in Hematology and Oncology H&o 4(8): 588-590
2006
ISSN/ISBN: 1543-0790 PMID: 17111557 Document Number: 600021
Document emailed within 1 workday
Related Documents
Greco, C.; Castiglioni, S.; Fodor, A.; Mazzetta, C.; De Cobelli, O.; Orecchia, R. 2004: Androgen ablation therapy does not increase the risk of late morbidity following 3D-conformal radiotherapy of organ-confined prostate cancer: the experience of the European Institute of Oncology Tumori 90(6): 567-572Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319
Nguyen, P.L. 2015: Radiation therapy for node-positive prostate cancer: it's time for a randomized trial Oncology 29(2): 116-117
Mostaghel, E.A.; Lin, D.W.; Amory, J.K.; Wright, J.L.; Marck, B.T.; Nelson, P.S.; Matsumoto, A.M.; Bremner, W.J.; Page, S.T. 2012: Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial Journal of Clinical Endocrinology and Metabolism 97(8): 2809-2817
Beuzeboc, P.; Richaud, P. 2003: Androgen replacement therapy and prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(5 Suppl 2: 1276-1277
Roux, C. 2003: Osteoporosis due to androgen suppression therapy in men with prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(2 Suppl 1: 24-27
Buyyounouski, M.K. 2010: Androgen deprivation therapy in high-risk prostate cancer Oncology 24(9): 806; 809
Arai, G.; Okada, H. 2016: Androgen deprivation therapy for prostate cancer: adverse effects and their management Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 605-609
Pettaway, C.A. 1999: Racial differences in the androgen/androgen receptor pathway in prostate cancer Journal of the National Medical Association 91(12): 653-660
Ying, J.; Yao, D.-H.; Ren, X.-M. 2003: Study of sexual hormone changes in prostate cancer patients before and after androgen deprivation therapy Zhonghua Nan Ke Xue 9(3): 191-192; 196
Hu, Y.-H.; Guo, J.-C.; Zhang, M. 2017: Bipolar androgen therapy: a novel therapeutic strategy for castration-resistant prostate cancer Zhonghua Nan Ke Xue 23(12): 1138-1140
Alvarez Rodríguez, S.; Alonso Gordoa, T.; Burgos Revilla, F.Javier. 2018: Current status of androgen deprivation therapy in hormone-sensitive prostate cancer Archivos Espanoles de Urologia 71(3): 247-257
Bastos, D.A.; Dzik, C.; Rathkopf, D.; Scher, H.I. 2014: Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology 28(8): 693-699
Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; Von Hoff, D.D. 1999: 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells Anticancer Research 19(2a): 1285-1291
Williams, M.E. 2004: ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma Current Hematology Reports 3(6): 395-396
Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Kern, S.; Lee, D.; Wang, V.; Leysens, M.; Higgins, B.; Martin, J.; Gerald, W.; Dracopoli, N.; Cordon-Cardo, C.; Scher, H.I.; Hampton, G.M. 2000: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1 Cancer Research 60(21): 6134-6141
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Wilt, T.J.; Paul, J.; Murdoch, M.; Nelson, D.; Nugent, S.; Rubins, H.B. 2001: Educating men about prostate cancer screening. a randomized trial of a mailed pamphlet Effective Clinical Practice: Ecp 4(3): 112-120
Boel, K.; Van Poppel, H.; Goethuys, H.; Derluyn, J.; Vandenbroucke, F.; Popelier, G.; Casselman, J.; Billiet, I.; Vanuytsel, L.; Paridaens, R.; Baert, L. 1999: Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial Anticancer Research 19(3b): 2157-2161
2015: (P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)? Oncology 29(4 Suppl. 1)